News

The center will combine molecular and cell biologists to provide them with genomics and genotypic data for assessment of biological pathways, disease mechanisms and the characterization of healthy

The deal, which is anticipated to complete in January 2013, is subject to certain closing conditions. Bio-Rad life science group president Brad Crutchfield said, "With this acquisition, Bio-Rad

The activities of Teva-Handok business venture are anticipated to begin in few months subsequent to the issuance of approvals by the regulatory bodies. Teva South Korea chairman, business

Efficacy of the monoclonal anti-toxin medication against inhalational anthrax, caused due to Bacillus anthracis, was established in studies conducted in animal models while the safety profile was demonstrated

The only approved pituitary-directed therapy in the US, for the patients who are not suitable for pituitary surgery, addresses the principal mechanism of Cushing’s disease. Novartis Oncology president

The antisense drug ISIS-TTR, a part of the Isis-GSK strategic RNA therapeutic alliance, is being developed for the treatment of transthyretin (TTR) amyloidosis. TTR amyloidosis is a severe

Viread is indicated for HIV-1 infected children between two to six years of age and for HIV-1 infected children more than six years for whom solid dosage is

Under the agreement, UMN Pharma and its subsidiary, UNIGEN, will use Catalent’s GPEx technology for producing a number of biosimilars. UMN Pharma said for product development including clinical

The collaboration will also be involved in evaluating the new therapeutics in proof-of-concept clinical trials. To implement the development, the companies will form a Therapeutic Innovation Group (TIG),